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Vascular endothelial growth factor–C promotes
vasculogenesis, angiogenesis, and collagen
constriction in three-dimensional collagen gels
Stephen M. Bauer, MD,a Richard J. Bauer, PhD,a Zhao-Jun Liu, MD, PhD,b Haiying Chen, MD,a Lee
Goldstein, MD,a and Omaida C. Velazquez, MD,a Philadelphia, Pa
Objective: Neovascularization, angiogenesis, and collagen constriction are essential for wound healing. We tested whether
vascular endothelial growth factor–C (VEGF-C) can promote collagen constriction, capillary sprouting (angiogenesis),
and invasion/migration of bone marrow–derived endothelial progenitor cells into collagen (vasculogenesis).
Methods: We used a recently characterized three-dimensional collagen matrix assay with either monolayers of human
dermal microvascular endothelial cells (HMVECs) or bone marrow–derived endothelial progenitor cells (BMD EPCs),
obtained from Tie-2 LacZ transgenic mice, overlaid with an acellular layer and then a cellular layer of collagen embedded
with fibroblasts, that were nontransduced or transduced with either LacZ adenoviral vector (Ad5) or VEGF-C/Ad5. The
ability of VEGF-C to enhance fibroblast-mediated collagen constriction was measured, and gels overlying HMVECs or
BMD EPCs were co-cultured, harvested, and assayed for HMVEC migration, sprouting, and capillary-like formation;
gels containing BMD EPCs were assayed for EPC invasion/migration into the collagen extracellular matrix.
Results: VEGF-C significantly increased collagen constriction and formation of capillary-like structures with true lumina
(P < .05) assessed by von Willebrand factor and VEGF receptor-2 immunoassaying. VEGF-C induced a significant
increase in HMVEC migration, tubular polarization, and branching sprouts associated with a significant up-regulation
of membrane type 1 matrix metalloproteinase (MT1-MMP) (P< .05). Fibroblasts were necessary to support BMD-EPC
invasion/migration from the monolayer into the collagen. Moreover, fibroblasts overexpressing VEGF-C significantly
enhanced EPC invasion/migration (P < .05) into the extracellular matrix by two-fold, and this effect could not be
achieved with equivalent levels of exogenous VEGF-C in the absence of fibroblasts. The addition of a soluble VEGF-C
competitor protein only partially inhibited these responses, reducing the EPCs by three-fold, but significant numbers of
EPCs still invaded/migrated into the extracellular matrix, suggesting that other fibroblast-specific signals also contribute
to the vasculogenic response.
Conclusion: Fibroblast-specific expression of VEGF-C promotes collagen constriction by fibroblasts and enhances
microvascular endothelial cell migration, branching, and capillary sprouting in association with up-regulating MT1-
MMP expression. Fibroblasts are necessary for BMD EPC invasion/migration into collagen, and their overexpression of
VEGF-C enhances this fibroblast-mediated vasculogenic effect. Collectively, these findings suggest a role for VEGF-C in
multiple biologic steps required for wound healing (angiogenesis, vasculogenesis, and collagen constriction). ( J Vasc
Surg 2005;41:699-707.)
Clinical Relevance: Ischemic wound healing remains an unsolved problem with no previously identified molecular target
for therapeutic intervention. This study demonstrates that VEGF-C overexpression by fibroblasts stimulates multiple
biologic processes known to impact wound healing, such as collagen constriction, capillary sprouting, and EPC invasion
and migration through extracellular matrix. Most ischemic wounds fail to heal and frequently lead to major limb
amputation. Available cytokine ointments are ineffective, and revascularization is often not technically feasible. Even
when these procedures are accomplished, many ischemic wounds frequently still do not heal because of multifactorial
tissue level impairments in the fibroblastic and neovascularization responses at the wound base. Our findings identify an
important role for two novel tissue level targets, dermis-derived fibroblasts and VEGF-C, in collagen constriction,
angiogenesis, and postnatal vasculogenesis from BMD EPCs. Thus the findings are particularly relevant to the unsolved
clinical problem of ischemic wound healing.The healing cascade of all wounds ultimately requires
neovascularization, collagen deposition, and collagen con-
striction by myofibroblasts. Neovascularization in the adult
is known to occur by two distinct processes, angiogenesis
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doi:10.1016/j.jvs.2005.01.015and vasculogenesis.1 Angiogenesis is the process whereby
new capillaries grow from pre-existing mature capillaries
(ie, from resident endothelial cells) by sprouting, intussus-
ception, or elongation.1-5 Angiogenesis requires digestion
of basement membrane and extracellular matrix proteins by
metalloproteinases. Specifically membrane type 1 matrix
metalloproteinase (MT1-MMP) is known to be involved in
the polarization of endothelial cells to form tubules during
capillary sprouting.6
Vasculogenesis is the de novo formation of cord-like
structures from the differentiation of progenitor stem cells,
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vasculogenesis, EPCs arise from the bone marrow, and
approximately 0.002% of the circulating mononuclear cell
fraction of whole blood are EPCs.1,7-9 When necessary,
EPCs enter the peripheral circulation to augment the cir-
culating pool and follow cytokine gradients to traffic into
areas of neovascularization, where they subsequently exit
the circulation and invade/migrate through the extracellu-
lar matrix (ECM).8-11
Cytokines, cell-matrix, and cell-cell interactions influ-
ence both endothelial cell (ECs) and EPC activation and
recruitment into angiogenesis and vasculogenesis, respec-
tively. The most important family of cytokines implicated in
the neovascularization processes is the vascular endothelial
growth factor (VEGF) family, composed of VEGF-A,
VEGF-B, VEGF-C, VEGF-D, and placenta growth fac-
tor.1,12 The role of VEGF-A in activating the angiogenic
phenotype of resident ECs as well as recruiting EPCs is well
established.1,11,13 However, other VEGF family members
have not yet been implicated to be as effective, but recent
evidence demonstrated that VEGF-C, once thought to
only play a role in lymphangiogenesis,14 might also be an
important regulator of both angiogenesis and vasculogen-
esis.10,15-18
VEGF-C mediates its lymphangiogenic effects through
VEGF receptor-3 (VEGFR-3).16 In addition, VEGF-C, via
its actions on VEGF receptor-2 (VEGFR-2), might play a
role in angiogenesis through signaling pathways that are
likely redundant to those mediated by VEGF-A.10,12,17,18
But VEGF-C’s roles in processes central to postnatal vas-
culogenesis or wound healing have not been previously
studied.
We used a previously characterized in vitro three-di-
mensional collagen matrix assay (3-DCMA)19,20 to study
the role of VEGF-C on angiogenesis, vasculogenesis, and
wound healing. Previously we used our 3-DCMA to report
that fibroblasts play an essential role in the phenotypic
differentiation of mature ECs from monolayer to capillary
morphology via cytokine and cell-cell signals.19,20 With this
same model, we currently demonstrate VEGF-C’s role in
stimulating fibroblast-mediated collagen constriction, for-
mation of capillary networks from mature EC monolayers,
and invasion/migration of EPCs in type I collagen ECM.
MATERIALS AND METHODS
Cells
All cells and co-cultures were incubated at 37°C in 98%
humidified air containing 5% CO2.
Fibroblasts. Primary cultures of human dermal fibro-
blasts were initiated as explant cultures from trypsin-treated
and epidermis-stripped neonatal foreskin as previously re-
ported21 and cultured in Dulbecco modified Eagle medium
(DMEM) with glutamine (Gibco/BRL, Gaithersburg,
Md), 8 mmol/L HEPES (Sigma, St Louis, Mo), and 10%
fetal bovine serum (FBS) (Hyclone, Logan, Utah).
Human dermal microvascular endothelial cells.
Primary human dermal microvascular endothelial cells(HMVECs), provided by Dr D. Fraker, University of Penn-
sylvania, Philadelphia, Pa, were isolated and cultured as
previously described22,23 on plates coated with collagen
type I (Organogenesis, Canton, Mass; 1 mg/mL) and
passaged in Endothelial Growth Medium Bulletkit (EGM;
Clonetics/Cambrex Biosciences; catalogue # CC-3124).
293 cells. Used for the generation of adenoviral vec-
tors, these cells are immortalized and transformed by ade-
novirus E1A and E1B genes and were obtained from the
Vector Core of the Institute for Human Gene Therapy,
University of Pennsylvania, Philadelphia, Pa, and grown in
DMEM with 10% FBS.
Transgenic Tie2/LacZ bone marrow–derived
EPCs. Bone marrow–derived EPCs (BMD EPCs) were
isolated from murine bone marrow–derived mononuclear
cell fraction from 4-week-old Tie2/LacZ heterozygote
transgenic mice (FVB/N-TgN[TIE2LacZ]182Sato; The
Jackson Laboratory, Bar Harbor, Maine) and cultured as
previously described.24,25 The Tie-2 receptor binds angio-
poietin-1 (Ang-1) ligand and is expressed only on cells of
the endothelial lineage, and the Tie2/LacZ transgenic
mouse is a heterozygote in which one allele has the Tie-2
promoter coupled with the LacZ reporter gene that en-
codes for -gal expression on Tie-2 expression, making this
system effective for tracking BMD EPCs that differentiate
into the endothelial lineage.
Briefly, femurs were flushed with ice-cold phosphate-
buffered saline (PBS), and the mononuclear cell fraction
was subsequently isolated by density centrifugation over
Ficoll. Then, 1  106 cells were plated on 24-well plates
coated with 20 ng/mL of fibronectin in Endothelial
Growth Medium-2 Bulletkits (EGM-2; Clonetics/Cam-
brex Biosciences; catalogue # CC-3162). After 4 days of
culture the medium was changed, nonadherent cells were
discarded, and the adherent cells were cultured in EGM-2.
After 20 days of culture, colonies of BMD EPCs were
confirmed to differentiate into mature endothelial cells
staining positive for CD 31 (PECAM-1), von Willebrand
factor (vWF), -gal expression, and endothelial-specific
lectin and demonstrating uptake of dioctadecyl-3,3,3=,
3=-tetramethylindocarboyanine perchlorate-acetylated-low
density lipoprotein (DiI-acLDL) uptake. DiI-acLDL (Mo-
lecular Probes Inc, Eugene, Ore) uptake and UEA-1 lectin
binding assay (fluorescein isothiocyanate [FITC] labeled
lectin from Ulex europaeus [UEA-1 lectin]; Sigma-Aldrich,
Inc) were performed by replacing the BMD EPC culture
medium with medium containing 10 g/mL DiI-ac-LDL
and incubating for 1 hour at 37° C. Medium was removed,
and cells were washed three times with PBS and then fixed
in Prefer. Lectin was added at a concentration of 10
g/mL and incubated at room temperature for 1 hour.
Finally, nuclei were counterstained with Hoechst, and
slides were examined under fluorescent microscopy.
Antibodies
Primary antibodies. Rabbit polyclonal anti-human
MT1-MMP antibody was purchased from Chemicon In-
ternational (Temecula, Calif). Mouse monoclonal anti-
VEG
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drich Inc. Mouse monoclonal anti-human vWF antibody
was purchased from NeoMarkers Inc (Fremont, Calif). Rat
monoclonal anti-mouse PECAM-1 antibody, goat poly-
clonal MMP-2, and goat polyclonal TIMP-2 were all ob-
tained from Santa Cruz Biotechnology, Inc (Santa Cruz,
Calif).
Secondary antibodies. Biotinylated goat anti-rabbit
immunoglobulin G (IgG) was obtained from Vector Labs
(Burlingame, Calif). Biotinylated horse anti-mouse IgG
was purchased from Jackson Immunoresearch Labs, Inc
(Westgrove, PA). FITC-conjugated rabbit anti-goat IgG
was obtained from Santa Cruz Biotechnology. Alexa Flour
488 green fluorescent goat anti-mouse IgG was obtained
from Molecular Probes Inc.
Recombinant proteins
Recombinant human VEGF-C (rhVEGF-C) and re-
combinant human VEGF R3/Fc chimera protein (rh-
VEGF-R3/Fc) were both obtained from R&D Systems
(Minneapolis, Minn) and were added in concentrations of
100 ng/mL and 20 g/mL, respectively (saturating doses
based on prior studies and manufacturer recommenda-
tion).
Vectors
Recombinant adenoviral vectors were provided by Dr
M. Herlyn, The Wistar Institute, Philadelphia, Pa. Briefly,
vectors were generated by homologous recombination in
293 cells.19,20,26  LacZ/Ad-5, used as a control adenoviral
vector, was obtained from the Vector Core of Human Gene
Therapy Institute, University of Pennsylvania, and is an
E1/E3-deleted recombinant virus producing the -galac-
tosidase protein. To construct VEGF-C/Ad-5, a human
Fig 1. VEGF-C enhances fibroblast-mediated collagen
cell monolayer consisted of no cells for collagen constric
network formation, and BMD EPCs for EPC invasion/m
consisted of collagen only; rhVEGF-C (100 ng/mL);
nontransduced fibroblasts; fibroblasts transduced with
transduced with VEGF-C/Ad-5 (100 PFU, VEGF-C)
constriction by nontransduced fibroblasts (control), fibro
LacZ), or fibroblasts transduced with VEGF-C/Ad-5 (1
measurements of gel maximum diameter. *P  .001 forVEGF-C cDNA was amplified by polymerase chain reac-tion and confirmed by sequencing. DL7001 Ad5 plasmid
lacking the E1 and E3 genes was used to generate this
adenoviral vector. The recombinant viruses were propa-
gated in 293 cells and purified by using cesium chloride.
Before infection of human fibroblasts (at 100 plaque-form-
ing units [PFU]), the adenoviral vectors were titrated in
293 cells to determine PFU as described.27 Functional
secretion of soluble factors by fibroblasts transduced with
adenoviral vectors was previously characterized by enzyme-
linked immunosorbent assay (ELISA) analysis of culture
medium to start 24 to 48 hrs after transduction.19,20,26
Twenty-four hours before the construction of 3-DCMA,
the fibroblasts to be embedded were separated into three
groups: nontransduced (control), transduced with control
vector LacZ/Ad-5 (100 PFU, LacZ), or transduced with
VEGF-C/Ad-5 (100 PFU, VEGF-C).
Collagen constriction assay
A schematic illustration of the layers for the three-
dimensional (3-D) collagen gels used to assay for collagen
constriction is depicted in Fig 1, A. This method has been
previously reported.19,20 Briefly, an acellular layer of type I
collagen was overlaid with a layer of fibroblast-embedded
collagen type I (5  105 cells/mL). Acellular-to-cellular
collagen layers were plated 1:3 ratio by volume in 6-well
plates. After polymerization of the collagen, culture me-
dium was added. Fresh medium (DMEM, 10% FBS) was
replenished every 48 hours, and collagen constriction was
measured daily by caliper measurements of gel maximum
diameter.
3-DCMA
Reconstruction of capillary-like structures in 3-D col-
lagen gels was performed as previously described19 and
riction. (A) Schematic illustration of the 3-DCMA. The
HMVECs for MT1-MMP expression, capillary-like EC
ion into ECM. The upper experimental layer of collagen
GF-C (100 ng/mL) and VEGF-R3/Fc (20 ng/mL);
ol vector LacZ/Ad-5 (100 PFU, LacZ); or fibroblasts
and without VEGF-R3/Fc (20 ng/mL). (B) Collagen
s transduced with control vector LacZ/Ad-5 (100 PFU,
U, VEGF-C) was measured daily for 15 days by caliper
F-C vs Control and LacZ.const
tion,
igrat
rhVE
contr
with
blast
00 PFdepicted in Fig 1, A. Briefly, 24-well plates were plated with
JOURNAL OF VASCULAR SURGERY
April 2005702 Bauer et aleither HMVEC monolayers, cultured to 80% confluency,
or confluent monolayers of BMD EPCs and then overlaid
with a 1-mm thick layer of acellular collagen type I (1
mg/mL) prepared in M199 medium supplemented with
L-glutamine, sodium bicarbonate, heparin (100 U/mL),
vitamin C (50 g/mL), and FBS (1%). After polymeriza-
tion of the collagen gels, the cells were overlaid with a
second (3-mm thick) collagen layer containing the appro-
priate conditions. Conditions consisted of acellular colla-
gen only, 100 ng/mL of rhVEGF-C added to the collagen
and culture medium, 5  105 cells/mL fibroblasts that
were nontransduced (no vector), transduced with LacZ/
Ad-5 at 100 PFU, or transduced with VEGF-C/Ad-5 at
100 PFU, and finally 20g/mL of VEGF-R3/Fc. The gels
containing HMVECs were cultured in EGM medium, and
gels containing BMD EPCs were cultured with EGM-2. All
3-DCMAs were incubated at 37°C for 7 days for the cross
sections (allowing time for optimal collagen constriction)
and 5 days for the whole mounts (a time point where the
gels are still translucent by virtue of less collagen constric-
tion). Fresh medium was replenished every 48 hours.
Evaluation of 3-D collagen gels
At the completion of each experiment, each gel was
fixed, lifted from its incubation well, and either processed as
a whole mount or embedded in paraffin and serially sec-
tioned.
Whole mounts were analyzed by immunofluorescence
with anti-human vWF as previously described.20 Briefly
gels were stained with monoclonal anti-vWF VIII Ab fol-
lowed by an Alexa Flour 488 green fluorescent goat anti-
mouse second antibody and counterstained with Hoechst
dye (bisBenzamide at 10 mg/mL). vWF () endothelial
cell networks were examined and photographed by in-
verted fluorescence microscopy.
Immunohistochemistry was performed on gels embed-
ded in paraffin and serially sectioned for staining with the
appropriate antibodies. Immunohistochemistry was done
by using standard procedures of deparaffinizing and rehy-
dration of sections, blocking of tissue with 10% serum, and
then incubating with primary and secondary antibodies/
reagents.19 Negative control stains with no primary anti-
body or an irrelevant primary antibody were routinely
included in all experiments.
-galactosidase assay was performed by removing me-
dium and fixing the gels for 10 minutes in 0.5% glutaralde-
hyde at room temperature. Gels were then washed twice
with PBS/MgCl solution for 10 minutes each wash. The
gels were incubated with X-gal at 37°C overnight. The
following day the gels were fixed in Prefer and embedded in
paraffin.
Medium after 2 days of co-culture in our 3-D collagen
gels was assayed with a VEGF-C ELISA obtained from
Zymed Laboratories (San Francisco, Calif) and was per-
formed according to manufacturer’s instructions.Statistical analysis
All experiments were performed in duplicates and in-
dependently repeated four times. Quantification was per-
formed in at least 10 random high power fields (HPF) of
whole mounted gels or each serial cross section; data are
presented as means  standard error of mean. Microsoft
Excel (Microsoft Corp, Redmond, Wash) was used for
statistical analysis. 2 or two-tail t test was used for statistical
comparisons of noncontinuous or continuous data, respec-
tively. P value .05 was considered statistically significant.
RESULTS
We used our 3-DCMA (Fig 1, A) to test the hypotheses
that VEGF-C enhances the angiogenic responses, collagen
constriction, MT1-MMP expression, capillary-like EC net-
work formation, and the vasculogenic response, EPC inva-
sion/migration into ECM.
VEGF-C overexpression in fibroblasts increases
collagen constriction. Fibroblasts constrict type I colla-
gen matrices via V3 and 21 integrins under the regu-
lation of growth factors and cytokines28 and are pivotal to
the contraction of the wound base and healing by second-
ary intention.29 We investigated the effect of VEGF-C
overexpression on collagen constriction by transducing
fibroblasts VEGF-C/Ad5 to induce overexpression of
VEGF-C. VEGF-C overexpressing fibroblasts significantly
increased collagen constriction (P  .001) from days 6
through 15 when compared to the controls of nontrans-
duced fibroblasts or fibroblasts that were transduced with
LacZ/Ad5, where the rate deviated most rapidly from the
control gels at days 4 through 7 (Fig 1, B).
VEGF-C overexpression in fibroblasts increases
MT1-MMP expression. MT1-MMP is up-regulated in
the basolateral cell membrane of activated ECs and medi-
ates capillary sprouting from pre-existing mature capillar-
ies.30 To determine the effects of fibroblasts overexpressing
VEGF-C, we quantified MT1-MMP expression by immu-
nohistochemistry. Three-fold more MT1-MMP () HM-
VECs invaded and migrated through the layers of the
3-DCMA with VEGF-C overexpressing fibroblasts when
compared to controls (Fig 2, A, B, D), whereas these cells
constitutively expressed very low matrix metalloprotein-
ase-2 or tissue inhibitor of metalloproteinase (data not
shown). Furthermore, many MT1-MMP() HMVECs
were polarized into networks of sprouting branching tubes
that spanned the layers of the collagen gels (Fig 2, C).
Fibroblast overexpression of VEGF-C stimulates
HMVECs to invade and migrate through collagen,
forming capillary-like branching tubules with lumina.
To characterize the extent of capillary-like network forma-
tion mediated by fibroblasts and growth factor overexpres-
sion within our 3-DCMA, we stained for the cell surface
expression of VEGFR-2 and cytoplasmic expression of
vWF. When VEGF-C overexpressing fibroblasts were used
in the 3-DCMA, significantly greater number and more
complex interconnecting HMVEC networks resembling
true capillaries were observed within the collagen gels as
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(Fig. 3) and VEGFR-2 immunohistochemistry of serial
perpendicular cross sections (Fig 4).
Fibroblasts support BMD EPC invasion/migration
through collagen and fibroblasts overexpressing
VEGF-C significantly increased these vasculogenic
effects. EPC invasion and migration through avascular or
ischemic ECM after EPCs are mobilized into circulation
from the bone marrow stem cell pool are fundamental to
postnatal vasculogenesis.7-9,24,25 To test the hypothesis
that fibroblasts might support early steps of vasculogenesis,
we added BMD EPCs by using culture conditions that
favor the survival of EPC.24,25 Because these BMD EPCs
were derived from Tie-2 LacZ transgenic mice, they are
easily identified by their ability to express -galactosidase.
Fig 2. VEGF-C up-regulates expression of MT1-MM
collagen type I–coated 24-well plates and overlaid with
with fibroblasts (5  105 cells/mL) (Fig 1, A). Twenty-
to be embedded were separated into three groups: non
Ad-5 at 100 PFU (LacZ), or transduced with VEGF-C/
were fixed, embedded in paraffin, and assessed by serial p
representative cross sections stained for MT1-MMP
fibroblasts, (B, C) fibroblasts transduced with VEGF-C sh
of capillary-like networks (C). (D) Quantification of over
cells per 40 HPF (10 random fields of six serial cros
VEGF-C vs control and LacZ). Representative micropho
used for quantification.The addition of fibroblasts to the ECM was required tosupport any significant invasion or migration of BMD
EPCs into the layers of the 3-D collagen ECM (Fig 5,
A-D). This vasculogenic effect was most pronounced when
we compared fibroblast-embedded collagen (29.9%) versus
collagen only (0.9%) (Fig 5, G). More notably, fibroblasts
overexpressing VEGF-C significantly enhanced BMD EPC
invasion/migration into the 3-DCMA by two-fold when
compared to nontransduced fibroblasts (Fig 5).
Fibroblasts are necessary for the observed VEGF-C
mediated angiogenic and vasculogenic responses. We
previously tested melanoma cell lines as well as acellular
collagen matrices and found that the angiogenic responses
were fibroblast-specific and mediated by a combination of
direct cell-cell interactions via the 3 integrins and fibro-
blast-secreted soluble factors by the VEGF-R2 recep-
HMVECs. Monolayers of HMVECs were plated on
lar collagen, followed by a layer of collagen embedded
ours before construction of the 3-D gel, the fibroblasts
uced (control), transduced with control vector LacZ/
at 100 PFU (VEGF-C). After 7 days of incubation, gels
dicular cross sections (A-C). Immunohistochemistry of
ounterstained with hematoxylin. (A) Nontransduced
ncreased staining for MT1-MMP (B) and increased areas
T1-MMP expression by the number of MT1-MMP ()
ions per gel; *P  .05 for fibroblasts transduced with
phs were obtained under the same magnification as thatP in
acellu
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100 ng/mL of recombinant human VEGF-C (rhVEGF-C)
to the upper collagen layer without fibroblasts as well as to
the media; (2) we replaced the fibroblasts with transduced
HMVECs that overexpressed VEGF-C; and (3) we tested
the effects of a specific VEGF-C inhibitor (Fig 5). Only
7.3% and 3.3% of the total cells observed were -galactosi-
Fig 3. VEGF-C stimulates HMVEC vWf-positive cap
whole mounts stained for vWF and counterstained with
plated on collagen type I–coated 24-well plates and ove
embedded with fibroblasts (5 105 cells/mL). Twenty-
to be embedded were separated into groups: nontransd
(100 PFU) (B) or LacZ/Ad5 control vector (100 PFU).
for vWF expression under gentle shaking conditions, co
mounted. Projection views of the whole-mounted gels w
microscopy. (C) Quantification of overall number of vW
HMVEC cells); 10 random 20 HPF were counted per
vector control or Ad5/LacZ control. Representative micr
that used for quantification.
Fig 4. VEGF-C stimulates the formation of VEGFR-2
of serial cross sections stained for VEGFR-2 and coun
plated on collagen type I–coated 24-well plates and ov
embedded with fibroblasts (5 105 cells/mL) as describ
3-D gel, the fibroblasts to be embedded were separated in
VEGF-C/Ad-5 (100 PFU) (B). After 7 days of incubatio
on a perpendicular axis, and immunostained for VEG
VEGFR-2 () lumina per 10 random60 HPF stand
nontransduced cells; six serial cross sections per gel;
Representative microphotographs were obtained underdase () EPCs when either VEGF-C overexpressing HM-VECs or rhVEGF-C, respectively, were used in our
3-DCMA. Both nontransduced and VEGF-C/transduced
fibroblasts supported a significantly higher number of EPCs
to invade and migrate into the ECM (Fig 5).
The addition of 20 g/mL of rhVEGF-R3/Fc signif-
icantly inhibited (by nearly three-fold; Fig 5, E-G) the
observed VEGF-C mediated angiogenic and vasculogenic
-like tubular networks. Immunohistochemistry of gel
hst (blue nuclear stain). Monolayers of HMVECs were
with acellular collagen, followed by a layer of collagen
hours before construction of the 3-D gel, the fibroblasts
Control (A) and Ad5-transduced with VEGF-C/Ad-5
5 days of incubation, the gels were fixed, immunostained
rstained with Hoechst, lifted from the well, and whole
alyzed and photographed by using inverted fluorescent
tubular networks (containing three or more connecting
*P  .05 for fibroblasts transduced with VEGF-C vs no
tographs were obtained under the same magnification as
illary-like structures with lumen. Immunohistochemistry
ined with hematoxylin. Monolayers of HMVECs were
with acellular collagen followed by a layer of collagen
Fig 1, A. Twenty-four hours before construction of the
o groups: nontransduced (A) and Ad5-transduced with
gels were fixed, embedded in paraffin, serially sectioned
. (C) Quantification depicts the average number of
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arrows in (B) point to some representative lumina.
me magnification as that used for quantification.illary
Hoec
rlaid
four
uced
After
unte
ere an
F ()
gel.
ophocap
tersta
erlaid
ed in
to tw
n, the
FR-2
ard e
blackresponses. This soluble chimeric protein, rhVEGF-R3/Fc,
JOURNAL OF VASCULAR SURGERY
Volume 41, Number 4 Bauer et al 705functions as a competitor by binding VEGF-C and prevent-
ing it from binding to its receptors.17 This inhibition,
however, was not complete. Instead, approximately 20%
more BMD EPCs were observed of those seen with colla-
gen only or with HMVEC containing gels (Fig 5, G),
suggesting that other fibroblast-specific signals are also
involved.
VEGF-C levels in medium from the 3-DCMA after 2
days of co-culture were assessed by ELISA. Fibroblasts
transduced with VEGF-C/Ad5 contained 14.4  1.3 ng
(mean  standard error of mean), and nontransfected
fibroblasts contained only 5.8  0.2 ng of VEGF-C. By
contrast, when rhVEGF-C was added to the 3-DCMA,
VEGF-C levels (12.5  0.6 ng) were similar to the levels
produced by fibroblasts transduced with VEGF-C/Ad5
(14.4  1.3 ng) as well as HMVECs transduced with
VEGF-C/Ad5 (9.1  1.7 ng). As expected, most of the
Fig 5. VEGF-C enhances EPC invasion and migration i
Tie-2 Lac Z transgenic mice, used for their ability to
fibroblast-embedded cellular collagen layers. Control gel
or collagen only), (B, rhVEGF-C  collagen) (C, VEG
construction of the 3-D gel, the fibroblasts to be emb
fibroblasts collagen) and Ad5-transduced with VEGF-
and (F, VEGF-C/Ad5-fibroblast  collagen  rhVEGF
from the original wells, fixed, stained for -galactosidase
ular cross sections (nuclear red counterstain). (A-F)
Quantification of the number of -gal cells within the
collagen only; *P .05 for VEGF-C/Ad5-fibroblast vs n
only and rhVEGF-C; **P .05 for VEGF-C/Ad5-fibro
by black arrows and insert in (E), all fibroblast containin
EPCs.secreted or exogenously added VEGF-C is absorbed bymatrix and cell receptors and not available as available
VEGF-C detectable by ELISA, but these data collectively
indicate that the observed VEGF-C–augmented and fibro-
blast-mediated vasculogenic response (Fig 5) and angio-
genic effects are fibroblast-specific and cannot be achieved
with equivalent levels of exogenous VEGF-C protein or
with other cell types such as HMVECs or melanoma cells
(data not shown).
DISCUSSION
By evaluating VEGF-C in our 3-DCMA, this report
demonstrates that VEGF-C (1) enhances fibroblast-medi-
ated collagen constriction, (2) up-regulates MT1-MMP,
(3) increases sprouting of capillary-like branching tubules
with true lumina from HMVEC monolayers into fibro-
blast-embedded collagen, and (4) its expression by fibro-
blasts enhances BMD EPC invasion and migration into
-DCMA. Bone marrow–derived mononuclear cells from
ress -galactosidase, were overlaid with acellular and
id of any fibroblasts were constructed (A, no fibroblasts
Ad5-HMVECs  collagen). Twenty-four hours before
d were separated into two groups: nontransduced (D,
-5 (100 PFU) (E, VEGF-C/Ad5-fibroblast collagen)
Fc). After 7 days of incubation, the gels were removed
l), paraffin-embedded, and assessed by serial perpendic-
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VEGF-C stimulates physiologic angiogenesis in addition to
its clear role in lymphangiogenesis.10,32 VEGF-C’s effects
are mediated by its receptors VEGFR-2 and VEGFR-3,
which both mediate proliferative and chemotactic re-
sponses in ECs.32 Furthermore, it has been shown that
VEGF-C induces in vitro dose-dependent mitogenic and
chemotactic effects on microvascular ECs and promotes
angiogenesis in vivo in ischemic rabbit hind limbs.10 Par-
ticularly the intravascular injection of recombinant
VEGF-C in ischemic rabbit hind limbs enhanced neovas-
cularization as measured by blood pressure ratios between
ischemic versus nonischemic limbs, angiography, and cap-
illary density.10
This study shows that fibroblasts expressing VEGF-C
stimulated HMVEC MT1-MMP expression by three-fold
more in our 3-DCMA as well as forming capillary-like
networks. MT1-MMP is pivotal in forming capillary-like
tubular structures by sprouting, in collagen-containing fi-
brin matrices in vitro and is also involved in angiogenesis in
a fibrinous exudate in vivo.6,30 These findings suggest that
the VEGF-C–mediated activation of the angiogenic phe-
notype in HMVECs occurs by up-regulating MT1-MMP,
one of three key mechanisms by which angiogenesis oc-
curs.2,3,33
We demonstrate that fibroblasts overexpressing
VEGF-C are essential for vasculogenesis, specifically BMD
EPC invasion/migration in type I collagen. Neither bio-
logically equivalent levels of exogenous VEGF-C nor
VEGF-C overexpression by endothelial cells is sufficient to
stimulate BMD EPC invasion/migration, but instead this
vasculogenic response requires the presence of fibroblast-
specific signals that are clearly augmented by VEGF-C.
BMD EPC migration/invasion is only partially inhibited by
the addition of rhVEGF-R3/Fc chimeric protein to the
3-DCMA, indicating that rhVEGF-R3/Fc inhibits the
VEGF-C effects to VEGF-R2 and VEGF-R3 but not the
specific fibroblast-mediated signals. Collectively this sug-
gests that fibroblasts are necessary for the observed vascu-
logenic effects, which are likely mediated by both direct
cell-cell interactions as well as secreted primary (VEGF-C)
and potentially secondary factors released by the activated
fibroblasts or EPCs.
Our results add to prior reports indicating VEGF-C’s
potential vasculogenic effect in embryonic cells.15,17 Re-
cent work in VEGF-C zebra fish knockout embryos and
transgenic embryos overexpressing soluble VEGFR-3 dem-
onstrated that VEGF-C was required for the developing
vasculature in the embryo.15 In addition, co-cultures of
para-aortic splanchnopleural mesoderm explants from
mouse embryos with stromal cells showed that VEGF-C
signaling through VEGFR-2 worked synergistically with
VEGF-A and that the binding of VEGF-C to VEGFR-3
indirectly regulated VEGFR-2 signaling.17
On the basis of the specific and significant inhibition
observed with rhVEGF-R3/Fc, it is likely that the observed
vasculogenic effects are mediated by either VEGFR-2
and/or VEGFR-3 and their second messenger phosphati-dylinositol 3-kinase, as reported for VEGF-A.17,19,20 Inte-
grin activation has been shown to modulate VEGF-medi-
ated cellular responses, but the extent to which integrins are
also involved, such as those reported for VEGF-A, requires
further investigation. Our finding that VEGF-C increases
fibroblast-mediated collagen constriction suggests that in-
tegrins are activated in these gels, because constriction of
type I collagen by fibroblasts is known to occur by the
activation of V3 and 21 integrins.
28 We previously
showed that V3 integrin inhibition almost completely
obliterates fibroblast-mediated capillary formation in our
3-DCMA and that V3 synergistically modulates VEGF-
A–induced angiogenesis.20
Alternatively, autocrine VEGF-C activation of fibro-
blasts might result in the release of other secondary growth
factors. ECM constriction in a wound healing by secondary
intention is known to occur by myofibroblasts, which are
further differentiated fibroblasts with contractile compo-
nents. Growth factors or cytokines, such as transforming
growth factor–, are known to regulate myofibroblast dif-
ferentiation.34 Our collagen constriction results suggest
that VEGF-C might play a role in fibroblast-to-myofibro-
blast differentiation, which might result from an integrin-
mediated mechanism, a secondarily secreted factor, or po-
tentially a direct VEGF-C effect via one of its receptors.
To our knowledge, this is the first report of vasculo-
genic stimulation by fibroblasts and VEGF-C on adult
BMD cells. This work further enhances the growing evi-
dence for VEGF-C as an important angiogenic factor and,
for the first time, identifies VEGF-C as a stimulator of
fibroblast-mediated collagen constriction. Although fur-
ther investigations on the molecular cascades involved and
in vivo confirmation are needed, these data offer insight
into novel methods to promote angiogenesis, postnatal
vasculogenesis, and collagen constriction. Collectively, by
focusing on fibroblasts and VEGF-C as novel targets, these
findings might contribute to the development of new ther-
apeutics for ischemic wound healing.
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